Xin Huang

Xin Huang

Auto-generated profile, based on publicly available information

Xin Huang

Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
XGXu-dong Gao
Xu-dong Gao
HCHebing Chen
Hebing Chen
XHXin Huang
Xin Huang
HLHao Li
Hao Li
ZLZhen Liu
Zhen Liu
XBXiaochen Bo
Xiaochen Bo
Background: Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect does not satisfy initial expectation. Therefore, it is important to develop more effective molecular targeted therapeutic strategies for advanced HCC. Materials and methods: The antitumor effects of sorafenib or ARQ-197, an antagonist of c-MET (tyrosine-protein kinase Met or hepatocyte growth factor receptor), were examined by MTT or in murine tumor model. The effect of ARQ-197 on epithelial–mesenchymal transition (EMT) or multidrug resistance (MDR) was examined by quantitative real-time PCR for the expression of related genes. The clearance of sorafenib in HCC cells was detected by liquid chromatography-mass spectrometry/mass spectrometry. Results: ARQ-197 treatment enhanced the sensitivity of HCC cells to sorafenib. Mechanistic studies indicated that ARQ-197 inhibited the expression of EMT- and MDR-related genes. Moreover, ARQ-197 treatment decelerated the clearance of sorafenib in cultured HCC cells and subcutaneous HCC tumors in nude mice. Conclusion: In the present work, our data suggested that ARQ-197 decelerated the clearance of sorafenib in HCC cells and enhanced the antitumor effect of sorafenib.

15 December 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZexian Zeng
Zexian Zeng
JFJingxin Fu
Jingxin Fu
CCCarrie Cibulskis
Carrie Cibulskis
AJAashna Jhaveri
Aashna Jhaveri
CGCurtis Gumbs
Curtis Gumbs
CWCatherine J. Wu
Catherine J. Wu
Purpose: Whole-exome (WES) and RNA sequencing (RNA-seq) are key components of cancer immunogenomic analyses. To evaluate the consistency of tumor WES and RNA-seq profiling platforms across different centers, the Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Cancer Immunologic Data Commons (CIDC) conducted a systematic harmonization study. Experimental Design: DNA and RNA were centrally extracted from fresh frozen and formalin-fixed paraffin-embedded non–small cell lung carcinoma tumors and distributed to three centers for WES and RNA-seq profiling. In addition, two 10-plex HapMap cell line pools with known mutations were used to evaluate the accuracy of the WES platforms. Results: The WES platforms achieved high precision (> 0.98) and recall (> 0.87) on the HapMap pools when evaluated on loci using > 50× common coverage. Nonsynonymous mutations clustered by tumor sample, achieving an index of specific agreement above 0.67 among replicates, centers, and sample processing. A DV200 > 24% for RNA, as a putative presequencing RNA quality control (QC) metric, was found to be a reliable threshold for generating consistent expression readouts in RNA-seq and NanoString data. MedTIN > 30 was likewise assessed as a reliable RNA-seq QC metric, above which samples from the same tumor across replicates, centers, and sample processing runs could be robustly clustered and HLA typing, immune infiltration, and immune repertoire inference could be performed. Conclusions: The CIMAC collaborating laboratory platforms effectively generated consistent WES and RNA-seq data and enable robust cross-trial comparisons and meta-analyses of highly complex immuno-oncology biomarker data across the NCI CIMAC-CIDC Network.

17 October 2020 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
SHSong He
Song He
YWYuqi Wen
Yuqi Wen
XYXiaoxi Yang
Xiaoxi Yang
ZLZhen Liu
Zhen Liu
XSXinyu Song
Xinyu Song
XBXiaochen Bo
Xiaochen Bo
The accumulation of various types of drug informatics data and computational approaches for drug repositioning can accelerate pharmaceutical research and development. However, the integration of multi-dimensional drug data for precision repositioning remains a pressing challenge. Here, we propose a systematic framework named PIMD to predict drug therapeutic properties by integrating multi-dimensional data for drug repositioning. In PIMD, drug similarity networks (DSNs) based on chemical, pharmacological, and clinical data are fused into an integrated DSN (iDSN) composed of many clusters. Rather than simple fusion, PIMD offers a systematic way to annotate clusters. Unexpected drugs within clusters and drug pairs with a high iDSN similarity score are therefore identified to predict novel therapeutic uses. PIMD provides new insights into the universality, individuality, and complementarity of different drug properties by evaluating the contribution of each property data. To test the performance of PIMD, we use chemical, pharmacological, and clinical properties to generate an iDSN. Analyses of the contributions of each drug property indicate that this iDSN was driven by all data types and performs better than other DSNs. Within the top 20 recommended drug pairs, 7 drugs have been reported to be repurposed. The source code for PIMD is available at https://github.com/Sepstar/PIMD/.

1 November 2010 in Applied Mechanics and Materials
Verified
Journal Article
Closed access
PDF file
Yingchao ZhangYingchao Zhang
Yingchao Zhang
Xiong XiongXiong Xiong
Xiong Xiong
CCChao Chen
Chao Chen
XHXin Yi Huang
Xin Yi Huang
A new particle swarm optimization based on dynamic parameter modification is proposed in this paper (Dynamic Parameter Modification Particle Swarm Optimizer, DPSO). In DPSO algorithm , is doing oscillating decay breaking through the constraint of topical linear decreasing, and the Euclidean distance and is calculated, which respectively stand for the Euclidean distances form the position of particle to the best position that the particle has passed and the best position that all the particles have passed under the time . Parameters and of topical PSO are modified dynamically based on the comparison of and in order to coordinate between global search and local search. Then find out the optimal value of Goldstein-Price function using topical PSO and the improved DPSO respectively, and the results demonstrate that compared to topical PSO, DPSO algorithm avoids falling into the local minimum and improves the search efficiency.

12 December 2025 in Radiation Medicine and Protection
Verified
Journal Article
Open access
YWYahe Wang
Yahe Wang
WLWenfeng Li
Wenfeng Li
NXNanxin Xu
Nanxin Xu
DXDafei Xie
Dafei Xie
XHXin Huang
Xin Huang
Ping-Kun ZhouPing-Kun Zhou
Ping-Kun Zhou